CymaBay Investor Sues For Books On $4.3B Gilead Merger
Law 360 M&A
MARCH 21, 2024
A shareholder of liver disease-focused biopharmaceutical company CymaBay Therapeutics Inc. sued the company in Delaware Chancery Court to extract more information over a proposed $4.3 billion merger with Gilead Sciences Inc.,
Let's personalize your content